It appears that Mesoblast has also completed the submission of its rolling BLA to the FDA for approval of its product candidate for acute gvhd.
From today's anouncement:
About MesoblastSee below for comparison:
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the- shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast completed submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates.
From previous announcement dated 27/11/2019 (Mesoblast Chairman Message to 2019 AGM)
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-theshelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast’s proprietary manufacturing process yields industrial-scale, frozen, off-the
You can verify the abvove info yourself by reading these two announcements.
- Forums
- ASX - By Stock
- MSB
- Submission of rolling BLA to the FDA for acute GVHD completed
Submission of rolling BLA to the FDA for acute GVHD completed
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.14 |
Change
0.000(0.00%) |
Mkt cap ! $1.307B |
Open | High | Low | Value | Volume |
$1.14 | $1.17 | $1.14 | $3.029M | 2.631M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 175076 | $1.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.14 | 211 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 140040 | 1.135 |
15 | 54955 | 1.130 |
11 | 57571 | 1.125 |
14 | 614736 | 1.120 |
7 | 35561 | 1.115 |
Price($) | Vol. | No. |
---|---|---|
1.140 | 49063 | 13 |
1.145 | 31515 | 8 |
1.150 | 70086 | 12 |
1.155 | 37755 | 9 |
1.160 | 137678 | 11 |
Last trade - 10.50am 19/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online